Percutaneous Intervention for Recurrent Aortic Insufficiency in a Patient With a Left Ventricular Assist Device and a Centrally Oversewn Aortic Valve
Raymond Bietry, Leora B. Balsam, Muhamed Saric, Doff B. McElhinney, Stuart Katz, Abe De Anda, Jr and Alex Reyentovich

Circ Heart Fail. 2013;6:e43-e44
doi: 10.1161/CIRCHEARTFAILURE.113.000301
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/6/4/e43

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org/subscriptions/
A 76-year-old man with severe degenerative aortic stenosis, coronary artery disease, and progressive congestive heart failure with severe systolic dysfunction underwent implantation of a Heartmate II left ventricular assist device (LVAD; Thoratec Corporation, Pleasanton, CA) after developing refractory cardiogenic shock. Because there was moderate aortic insufficiency (AI), the aortic valve was closed with a pledgeted central coaptation stitch that approximated the Noduli of Arantius with minimal residual regurgitation.

After initial clinical improvement, by 5 months after LVAD implantation, the patient was hospitalized with recurrent heart failure symptoms. Echocardiography revealed new onset moderate to severe AI with 2 dominant jets that were present during systole and diastole (Video I in the online-only Data Supplement, Figure). Over the next several months he developed worsening heart failure symptoms (class IIIb) with no evidence of LVAD malfunction. Concomitantly, his left ventricular end diastolic dimension increased from 4.3 cm to 5.8 cm. Right heart catheterization revealed a pulmonary capillary wedge pressure of 20 mm Hg with a cardiac index of 2.6 L/min. Surgical correction, including aortic valve replacement and closure of the left ventricular outflow tract were considered; however, because of the patient’s advanced age and 2 prior sternotomies, percutaneous closure of the aortic valve was pursued.

A 2-dimensional and 3-dimensional transesophageal echocardiography was used to deploy a 6 mm Amplatzer septal occluder device (St. Jude Medical, St. Paul, MN) between the left- and noncoronary cusps of the oversewn aortic valve. A second 5 mm Amplatzer device was deployed between the left- and right-coronary cusps of the aortic valve (Video II in the online-only Data Supplement). There was immediate improvement in the severity of aortic insufficiency after the procedure (Video III in the online-only Data Supplement).

Five months after the procedure the patient has only trace AI with class II heart failure symptoms and has been free of further heart failure hospitalizations. He has moderate hemolysis (lactate dehydrogenase preprocedure 195 IU/L and postprocedure 457 IU/L; normal reference range 98–192 IU/L) but his hemoglobin remains >10 g/dL and stable.

A growing number of patients with AI have undergone concomitant aortic valve surgery at the time of LVAD implantation to eliminate valvular insufficiency.1 These concomitant procedures include patch closure of the left ventricular outflow tract, replacement of the aortic valve with a bioprosthesis, or closure of the aortic valve with a central coaptation stitch. Little is known about the durability of these strategies, and in the case we report, the initial repair strategy was not durable. Regardless of the preoperative degree of AI, late onset of regurgitation is a well-recognized complication of continuous-flow LVAD placement, and it is associated with increased morbidity and mortality.2,3

The use of an Amplatzer device after LVAD placement to eliminate aortic insufficiency has been described previously.4 However, this is the first reported case to use multiple small Amplatzer devices to treat aortic insufficiency in a previously oversewn valve. The postprocedural concerns include hemolysis from peridevice regurgitant flow, obstruction of the coronary ostia, peridevice thrombus formation, erosion into the aortomitral curtain, and device embolization. Proper device selection (diameter and length) may prevent these complications. It is also important to note that this strategy for aortic valve closure results in complete LVAD dependency, and accidental power loss will likely be fatal.
Disclosures

None.

References


**Figure.** Transesophageal echocardiographic imaging during percutaneous treatment of eccentric aortic insufficiency. **A,** Aortic valve viewed en face by transesophageal echocardiography (TEE): 2 distinct commissural jets are noted, arising between the left- and noncoronary cusps and left-and right- coronary cusps. **C,** TEE is used to guide passage of a wire across the aortic valve between the left- and noncoronary cusps. Again, 2 distinct jets are seen. **B,** 2-Dimensional TEE imaging demonstrates the 2 Amplatzer devices after deployment. **D,** The Amplatzer devices as seen with 3-dimensional TEE imaging.

**Key Words:** 3-dimensional ▫ Amplatzer device ▫ aortic valve regurgitation ▫ echocardiography ▫ left ventricular assist device